intilaris LifeSciences has been providing optimized clinical development services to the global pharmaceutical companies for many years.
intilaris LifeSciences has been providing optimized clinical development services to the global pharmaceutical companies for many years.
intilaris has observed the disconnect of drug development between pharma and biotech and its impact on time to market and delays during regulatory assessment. intilaris has leveraged its pharma centric mindset, expertise in compliance with industry regulations to develop products which facilitate the alignment of Biotech’s creativity and innovation with Pharma’s reliability and stringency.
The first four products are directed to the Biotech leadership and the fifth product is available to both Biotech leadership and the Investor community with (or seeking a stake) in the Biotech.
- Readiness check for Preclinical
An assessment for Biotech Development Candidates in the research phase to make qualified decisions for the Preclinical Development. - Readiness check for Clinical
An assessment for Development Candidates in the Preclinical Development phase to assess the TPP and plan the Clinical Development. - Planning and Study Designs of Phase 1 / 2a studies
Delivered as a Service: A methodology to define the critical development path to Proof-of-Concept and design efficient Clinical Trials in exploratory development. - Planning and Study Designs of Phase 2b / 3 studies
Delivered as a Service: The continuation of the Clinical Development on the critical path to submission with a seamless integration to a co-development partner. - Clinical Asset Health Check for Investors
This product assesses the TPP and Clinical Development Program and places a rating on the likelihood of successfully completing the clinical development, receiving market authorization and generating revenue for the product(s). The report also recommends areas of rectification and its resulting impact on the rating.
We also announce a partnership with APAC Health Pty Ltd (‘APAC’), an Australian based global advisory firm to assist intilaris to deliver the products to the Biotech and Investor community.
Torsten Friedel, Managing Director at intilaris, says “we have observed a significant opportunity to shorten the time for new medicines to be taken through the clinic to the patient. We are confident that our quality-by-design structured development methodology, coupled with the depth of expertise by our staff will provide the Biotech and its stakeholders to achieve their commercial expectations, be it to out-license or take their products to the market.”
According to Dr. Djenan Ganic, Business Solution Director at intilaris, “APAC’s premiere global networks in the Biotech and Investor communities will enable intilaris to provide these products in many diverse regions, in addition to the major global Biotech hubs.
We are committed to make available our depth of big pharma expertise to the innovative Biotech community.”
“We are extremely pleased to partner with the Swiss team at intilaris and have been immensely impressed with the depth of the product offerings, which will no doubt positively impact to shorten the time to market for the next generation of medicines. The level of forethought by intilaris, in also developing a product for the investor stakeholder is unprecedented and will add transparency and confidence in Biotech funding.” says Dr. Chris Sotiropoulos, Director of APAC.
To learn more about these five products and how they may assist your organisation meet its goals, please contact us.
